MedTrace Logo

Eribulin in Advanced Solitary Fibrous Tumor

NCT03840772 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-09-20

No results posted yet for this study

Summary

Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin

Conditions

  • Solitary Fibrous Tumor

Interventions

DRUG

Eribulin

Treatment with eribulin

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • Italian Sarcoma Group

    lead NETWORK

Principal Investigators

  • Silvia Stacchiotti, MD · Fondazione IRCCS INT di Milano

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-17
Primary Completion
2024-09-18
Completion
2024-09-18

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03840772 on ClinicalTrials.gov